The authors empirically explore the revenue impact of marketing-mix variables and their interactions. The findings include the following: pharmaceutical direct-to-consumer advertising and detailing (sales force) affect demand synergistically, detailing raises price elasticity, and detailing has a higher return on investment than does direct-to-consumer advertising. The authors also discuss other implications and provide future research directions.
Get full access to this article
View all access options for this article.
References
1.
AzoulayPierre (2001), “Do Pharmaceutical Sales Respond to Scientific Evidence? Evidence from Anti-ulcer Drugs,” working paper, Management Department, Columbia University.
2.
BerndtErnst R., BuiLinda T., Lucking-ReileyDavid H., and UrbanGlen L. (1997), “The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the U.S. Antiulcer Drug Industry,” in The Economics of New Goods, BresnahanTimothy F., and GordonRobert J., eds. Chicago: University of Chicago Press, 277–322.
3.
BerrySteven (1994), “Estimating Discrete Choice Models of Product Differentiation,”RAND Journal of Economics, 25 (2), 242–62.
4.
BerrySteven, LevinsohnJames, and PakesAriel (1995), “Automobile Prices in Market Equilibrium,”Econometrica, 60 (4), 889–917.
5.
BlattbergRobert C., BrieschRichard, and FoxEdward (1995), “How Promotions Work,”Marketing Science, 14 (3, Part 2), G122–G132.
6.
CaponNoel, FarleyJohn U., and HoenigScott (1990), “Determinants of Financial Performance: A Meta-Analysis,”Management Science, 36 (10), 1143–59.
7.
ChintaguntaPradeep K., and DesirajuRamarao (2004), “Strategic Pricing and Detailing Behavior in International Markets,”Marketing Science, 23, forthcoming.
8.
ClarkeDarral G. (1976), “Economic Measurement of the Duration of Advertising Effects on Sales,”Journal of Marketing Research, 18 (November), 345–57.
GatignonHubert, and HanssensDominique M. (1987), “Modeling Marketing Interactions with Application to Sales Force Effectiveness,”Journal of Marketing Research, 24 (August), 247–57.
11.
GuadagniPeter M., and LittleJohn D.C. (1983), “A Logit Model of Brand Choice Calibrated on Scanner Data,”Marketing Science, 2 (3), 203–238.
12.
HorskyDan (1977), “Market Share Response to Advertising: An Example of Theory Testing,”Journal of Marketing Research, 14 (February), 10–21.
13.
KaulAnil, and WittinkDick (1996), “Empirical Generalizations About the Impact of Advertising on Price Sensitivity and Price,”Marketing Science, 14 (3), G151–G160.
14.
KuehnAlfred A. (1962), “Consumer Brand Choices: A Learning Process?”Journal of Advertising Research, 2 (December), 10–17.
15.
LambinJean-Jacques (1970), “Optimal Allocation of Competitive Marketing Efforts: An Empirical Study,”Journal of Business, 43 (4), 468–84.
16.
LeeflangPeter S.H., WittinkDick R., WedelMichel, and NaertPhilippe A. (2000), Building Models for Marketing Decisions.Norwell, MA: Kluwer Academic Publishers.
17.
LehmannDonald (2002), “Linking Marketing Decisions to Financial Performance and Firm Value,”MSI Executive Overview, (March), 1–5.
18.
LemonKatherine N., and NowlisStephen M. (2002), “Developing Synergies Between Promotions and Brands in Different Price–Quality Tiers,”Journal of Marketing Research, 39 (May), 171–85.
LittleJohn D.C. (1979), “Aggregate Advertising Models: The State of the Art,”Operations Research, 27 (July–August), 629–67.
21.
McFaddenD. F., and TrainK. (2000), “Mixed MNL Models for Discrete Response,”Journal of Applied Econometrics, 15 (5), 447–70.
22.
MelaCarl F., GuptaSunil, and LehmannDonald R. (1997), “The Long Term Impact of Advertising and Promotions on Consumer Brand Choice,”Journal of Consumer Research, 34 (2), 248–61.
23.
NerloveMarc, and ArrowKenneth J. (1962), “Optimal Advertising Policy Under Dynamic Conditions,”Economica, 29 (May), 129–42.
24.
NeslinScott A. (2001), “ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study,”Association of Medical Publications, (accessed May 22, 2004), [available at http://www.rappstudy.org].
25.
NevoAviv (2000), “A Practitioner's Guide to the Random Coefficients Logit Model of Demand,”Journal of Economics and Management Strategy, 9 (4), 513–48.
26.
NeweyWhitney K., and WestKenneth D. (1987), “A Simple, Positive Semi-Definite, Heteroskedasticity, and Autocorrelation Consistent Covariance Matrix,”Econometrica, 55 (3), 703–708.
27.
ParsonsLeonard J., and AbeelePiet Vanden (1981), “Analysis of Sales Call Effectiveness,”Journal of Marketing Research, 18 (February), 107–113.
28.
PelesYoram (1971), “Rates of Amortization of Advertising Expenditures,”Journal of Political Economy, 79 (September–October), 1032–59.
RizzoJohn A. (1999), “Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs,”Journal of Law and Economics, 42 (1), 89–116.
31.
RobertsMark J., and SamuelsonLarry (1988), “An Empirical Analysis of Dynamic, Non-Price Competition in an Oligopolistic Industry,”RAND Journal of Economics, 19 (2), 200–220.
32.
RosenthalMeredith B., BerndtErnst R., DonohueJulie M., EpsteinArnold E., and FrankRichard G. (2002), “Demand Effects of Recent Changes in Prescription Drug Promotion,” working paper, Department of Health Policy and Management, Harvard School of Public Health.
33.
SwinyardWilliam R., and RayMichael L. (1977), “Advertising-Selling Interactions: An Attribution Theory Experiment,”Journal of Marketing Research, 14 (November), 509–516.
34.
WittinkDick R. (2002), “Analysis of ROI for Pharmaceutical Promotions (ARPP),” paper presented to the Association of Medical Publications, (September 18, 2002), [available at http://www.vioworks.com/clients/amp].
35.
WosinskaMarta (2002), “Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products,” working paper, Harvard Business School.
